Abstract
BackgroundiPSC (induced pluripotent stem cells) banks of iPSC lines with homozygous HLA (human leukocyte antigen) haplotypes (haplobanks) are proposed as an affordable and off-the-shelf approach to allogeneic transplantation of iPSC derived cell therapies. Cord blood banks offer an extensive source of HLA-typed cells suitable for reprogramming to iPSC. Several initiatives worldwide have been undertaken to create national and international iPSC haplobanks that match a significant part of a population.MethodsTo create an iPSC haplobank that serves the Spanish population (IPS-PANIA), we have searched the Spanish Bone Marrow Donor Registry (REDMO) to identify the most frequently estimated haplotypes. From the top ten donors identified, we estimated the population coverage using the criteria of zero mismatches in HLA-A, HLA-B, and HLA-DRB1 with different stringencies: high resolution, low resolution, and beneficial mismatch.ResultsWe have calculated that ten cord blood units from homozygous donors stored at the Spanish cord blood banks can provide HLA-A, HLA-B, and HLA-DRB1 matching for 28.23% of the population.ConclusionWe confirm the feasibility of using banked cord blood units to create an iPSC haplobank that will cover a significant percentage of the Spanish and international population for future advanced therapy replacement strategies.
Highlights
Induced pluripotent stem cells hold great promise in the field of regenerative medicine due to their capacity to both self-renew and differentiate into any celltype of the human body
Haplotype frequencies A cohort of 30,000 randomized high-resolution Human leukocyte antigen (HLA) typing adult bone marrow donors from the Spanish Bone Marrow Donor Registry (REDMO) identified a total of 8478 different haplotypes for HLAA, HLA-B, and HLA-DRB1 (Fig. 1a and Supplementary Excel file for the complete list)
Identification of homozygous donors To identify homozygous cord blood units available in the Spanish banks that can be candidates as source cells to create the Induced pluripotent stem cells (iPSC) haplobank, we looked into the Spanish registry, which comprises 52,220 cord blood donations in Spain
Summary
Induced pluripotent stem cells (iPSC) hold great promise in the field of regenerative medicine due to their capacity to both self-renew and differentiate into any celltype of the human body. IPSC are free of ethical concerns and allow the autologous application of cell replacement therapies [1, 2]. There has been extensive research and development in the field to create safe iPSC and protocols to differentiate them into clinically relevant cells for cell therapy applications. The idea of using clinically matched iPSC for HLA-A, HLA-B, and Álvarez-Palomo et al Stem Cell Research & Therapy (2021) 12:233. IPSC (induced pluripotent stem cells) banks of iPSC lines with homozygous HLA (human leukocyte antigen) haplotypes (haplobanks) are proposed as an affordable and off-the-shelf approach to allogeneic transplantation of iPSC derived cell therapies. Several initiatives worldwide have been undertaken to create national and international iPSC haplobanks that match a significant part of a population
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
